Hexasol LA
Hexasol LA is a combination treatment of flunixin and oxytetracycline to effectively treat bovine respiratory disease where an anti-inflammatory and anti-pyretic effect is required. Hexasol LA is specifically formulated to provide initial anti-inflammatory for 24-36 hours and sustained anti-bacterial activity for 5-6 days following a single administration.
Target Species: Beef cattle, dairy cattle
-
Active Ingredient
Hexasol LA Solution for Injection for Cattle contains: Active Substances: Oxytetracycline (as dihydrate) 30% w/v (300mg/ml), Flunixin (as flunixin meglumine) 2.0% (20mg/ml).
-
Pharmaceutical Form
Solution for injection. A clear dark amber solution.
-
Indications
Specifically formulated to provide initial anti-inflammatory for 24-36 hours and sustained anti-bacterial activity for 5-6 days following a single administration. Indicated primarily for the treatment of bovine respiratory disease associated with Mannheimia haemolytica where an anti-inflammatory and anti-pyretic effect is required. In addition, a wide range of organisms are known to be sensitive in vitro to oxytetracycline, including Pasteurella spp, Arcanobacterium pyogenes, Staphylococcus aureus and certain mycoplasmas. The product may therefore be of use in the treatment of disease in cattle caused by such organisms where an anti-inflammatory and antipyretic effect is required.
-
Dosage
Indicated for deep intramuscular administration to cattle. The recommended dosage is 1 ml per 10 kg bodyweight (equivalent to 2 mg/kg flunixin and 30 mg/kg oxytetracycline) on a single occasion. Maximum volume per injection site: 15ml. If concurrent treatment is administered use a separate injection site. Additional therapy with an NSAID may be administered after 24 hours if required. Avoid the introduction of contamination.
Prefer to speak directly to a member of our team?
Norbrook GBÂ
We are open. Mon - Fri 9:00am - 5:00pm
Please note: Product information presented on this website is intended only as a brief summary of Norbrook products for your convenience. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information you should always consult a healthcare professional from your region or visit the local government agency website for the most up to date information. Please see our terms and conditions for further information.